-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Shareholders in MicroPort CardioFlow Medtech (HKG:2160) Have Lost 64%, as Stock Drops 20% This Past Week
Shareholders in MicroPort CardioFlow Medtech (HKG:2160) Have Lost 64%, as Stock Drops 20% This Past Week
Taking the occasional loss comes part and parcel with investing on the stock market. And unfortunately for MicroPort CardioFlow Medtech Corporation (HKG:2160) shareholders, the stock is a lot lower today than it was a year ago. In that relatively short period, the share price has plunged 64%. MicroPort CardioFlow Medtech may have better days ahead, of course; we've only looked at a one year period. The falls have accelerated recently, with the share price down 30% in the last three months. But this could be related to the weak market, which is down 13% in the same period.
After losing 20% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.
Check out our latest analysis for MicroPort CardioFlow Medtech
Because MicroPort CardioFlow Medtech made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
MicroPort CardioFlow Medtech grew its revenue by 58% over the last year. That's a strong result which is better than most other loss making companies. Meanwhile, the share price slid 64%. This could mean hype has come out of the stock because the bottom line is concerning investors. We'd definitely consider it a positive if the company is trending towards profitability. If you can see that happening, then perhaps consider adding this stock to your watchlist.
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
SEHK:2160 Earnings and Revenue Growth September 22nd 2022Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.
A Different Perspective
We doubt MicroPort CardioFlow Medtech shareholders are happy with the loss of 64% over twelve months. That falls short of the market, which lost 20%. There's no doubt that's a disappointment, but the stock may well have fared better in a stronger market. The share price decline has continued throughout the most recent three months, down 30%, suggesting an absence of enthusiasm from investors. Basically, most investors should be wary of buying into a poor-performing stock, unless the business itself has clearly improved. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for MicroPort CardioFlow Medtech you should be aware of.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
偶尔蒙受损失与投资股票市场密不可分。不幸的是,对于微港心流医疗科技公司(HKG:2160)股东们,今天的股价比一年前低了很多。在这段相对较短的时间内,该公司股价暴跌了64%。当然,MicroPort MedicoFlow Medtech可能会有更好的未来;我们只关注了一年的时间。股价最近加速下跌,在过去三个月里下跌了30%。但这可能与疲软的市场有关,同期市场下跌了13%。
在过去一周下跌了20%之后,有必要调查一下该公司的基本面,看看我们可以从过去的表现中推断出什么。
查看我们对MicroPort HearoFlow Medtech的最新分析
由于MicroPort MedicoFlow Medtech在过去12个月中出现亏损,我们认为市场可能更关注收入和收入增长,至少目前是这样。一般来说,没有利润的公司预计每年都会有收入增长,而且增长速度很快。这是因为快速的收入增长可以很容易地推断出预期利润,通常是相当大的规模。
在过去的一年里,MicroPort MedicoFlow Medtech的收入增长了58%。这是一个强劲的结果,比大多数其他亏损的公司都要好。与此同时,该公司股价下跌了64%。这可能意味着炒作已经从股票中出来,因为底线是投资者。如果该公司正在走向盈利,我们肯定会认为这是一个积极的因素。如果你能看到这种情况发生,那么也许可以考虑将这只股票添加到你的观察名单中。
你可以在下面看到收入和收入是如何随着时间的推移而变化的(点击图片可以发现确切的价值)。
联交所:2160盈利及收入增长2022年9月22日资产负债表的强健至关重要。也许很值得一看我们的免费报告其财务状况如何随着时间的推移而发生变化。
不同的视角
我们怀疑MicroPort MedicoFlow Medtech的股东对12个月来64%的损失感到满意。这一数字低于大盘,大盘下跌20%。毫无疑问,这令人失望,但在一个更强劲的市场中,该股很可能表现得更好。最近三个月,股价持续下跌,跌幅达30%,表明投资者缺乏热情。基本上,大多数投资者应该对买入表现不佳的股票保持警惕,除非业务本身已经明显改善。虽然值得考虑市场状况对股价可能产生的不同影响,但还有其他更重要的因素。一个恰当的例子:我们发现了1个微端口心脏流动医疗技术公司的警告标志你应该意识到。
如果你更愿意看看另一家公司--一家财务状况可能更好的公司--那么不要错过这一点免费已证明自己能够实现盈利增长的公司名单。
请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧